Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

CG Oncology (CGON) Shares Outstanding (2023 - 2026)

CG Oncology filings provide 3 years of Shares Outstanding readings, the most recent being $80.7 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 5.95% to $80.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $80.7 million, a 5.95% increase, with the full-year FY2025 number at $80.7 million, up 5.95% from a year prior.
  • Shares Outstanding hit $80.7 million in Q4 2025 for CG Oncology, up from $78.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $80.7 million in Q4 2025 to a low of $3.9 million in Q1 2023.
  • Median Shares Outstanding over the past 3 years was $67.1 million (2024), compared with a mean of $50.5 million.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 1627.96% in 2024 and later grew 5.95% in 2025.
  • CG Oncology's Shares Outstanding stood at $5.2 million in 2023, then soared by 1358.27% to $76.2 million in 2024, then rose by 5.95% to $80.7 million in 2025.
  • The last three reported values for Shares Outstanding were $80.7 million (Q4 2025), $78.3 million (Q3 2025), and $76.2 million (Q2 2025) per Business Quant data.